Speaker
That part of the portfolio is so volatile. You remember looking at these numbers. Korea this year has been five times more volatile than India and China. So, like you know you see this volatility in Hynix, you see this volatility in Samsung Electronics. And as we just ah touched upon, these companies are making really comfortable earnings. But despite that, these swings have been really wild. Incredible, yeah. And that's got to do with expectations. It's got to do simply with the market dynamics. But also there's a lot of leverage in system. People are borrowing um to make money. So if it goes down a bit, theyโฆ Any negative news tends to have quite outsized impact on the movement. Exactly. Now, we also have some EV stats. The EV industry is always good for stats. But what really surprised me here is that although we always think about electric vehicles as being a major export product from China, actually there's something else that's much bigger that I didn't really think about. And that's pharma out licensing, pharma. Pharma out-licensing is basically twice as much. It's twice as much. and like What is pharma out-licensing very quickly? ah So, like, you know, Chinese companies in the past were known for developing drugs on behalf of global peers because, like, you know, it was cheaper for them to do. Let's say somebody needs ah aspirin or Panadol and the Chinese says we can that much cheaper than it. Indians do that, Koreans do that, even Chinese do that. But now, like, you know, China is developing its own cures, drugs for certain diseases, say certain type of cancers or some type of really high-end antibodies. And now they get these cures patented. And now they offer these patents to global pharma companies.